{
    "body": "Have mutations in the Polycomb group been found in human diseases?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22869879", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23204235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23418308", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20506229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18668134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16397222", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16575874", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22328940", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22190018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16963837", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22237151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19904743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22431509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21921040"
    ], 
    "ideal_answer": [
        "Yes, different members of the Polycomb family have been found mutated in diseases such as primary microcephaly, nonsyndromic cleft lip and several cancers (including hemotopoietic malignancies, esophageal carcinoma, head and neck cancer or prostate cancer).\n\nExact anser:\nYes"
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.uniprot.org/uniprot/PC_DROME", 
        "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0031519"
    ], 
    "type": "yesno", 
    "id": "5176c6d08ed59a060a000032", 
    "snippets": [
        {
            "offsetInBeginSection": 543, 
            "offsetInEndSection": 831, 
            "text": "We identify a novel mutation in PHC1, a human orthologue of the Drosophila polyhomeotic member of polycomb group (PcG), which significantly decreases PHC1 protein expression, increases Geminin protein level and markedly abolishes the capacity to ubiquitinate histone H2A in patient cells.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418308", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1279, 
            "offsetInEndSection": 1407, 
            "text": "In clinical specimens of head and neck cancer, we found that coamplification of BMI1 and AURKA correlated with poorer prognosis.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204235", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1299, 
            "offsetInEndSection": 1413, 
            "text": "Mutations of EZH2, RUNX1, TP53, and ASXL1 were associated with shorter overall survival independent of the LR-PSS.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22869879", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 165, 
            "text": "In this study, we show the high frequency of spontaneous \u03b3\u03b4 T-cell leukemia (T-ALL) occurrence in mice with biallelic deletion of enhancer of zeste homolog 2 (Ezh2).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431509", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 892, 
            "offsetInEndSection": 1237, 
            "text": "Subsequently, analysis of deletion profiles of other PRC2 members revealed frequent losses of genes such as EZH2, AEBP2, and SUZ12; however, the deletions targeting these genes were large. We also identified two patients with homozygous losses of JARID2 and AEBP2. We observed frequent codeletion of AEBP2 and ETV6, and similarly, SUZ12 and NF1.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190018", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 273, 
            "offsetInEndSection": 434, 
            "text": "A total of 25 different EZH2 mutations were detected in 5.9% of PMF, 1.2% of PPV-MF, and 9.4% of PET-MF patients; most were exonic heterozygous missense changes.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21921040", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 326, 
            "offsetInEndSection": 732, 
            "text": "In the present investigation we have focused on the candidate region in 6p23, a region that have been found linked to CL/P in several investigations, in the attempt to find out the susceptibility gene provisionally named OFC1. Gene expression experiments in mice embryo of positional candidate genes revealed that JARID2 was highly and specifically expressed in epithelial cells in merging palatal shelves.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20506229", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 558, 
            "offsetInEndSection": 660, 
            "text": "High expression of EZH2 and amplification of EZH2 was found in 54.1% and 12.0% of ESCCs, respectively.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19904743", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1018, 
            "offsetInEndSection": 1256, 
            "text": "We also observed that HOXA9 levels were significantly inversely correlated with survival and that BMI-1 was overexpressed in cases with 11q23 rearrangements, suggesting that p19(ARF) suppression may be involved in MLL-associated leukemia.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668134", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1158, 
            "offsetInEndSection": 1378, 
            "text": "We demonstrate that in multiple experimental models of metastatic prostate cancer both BMI1 and Ezh2 genes are amplified and gene amplification is associated with increased expression of corresponding mRNAs and proteins.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16963837", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1512, 
            "offsetInEndSection": 1618, 
            "text": "he EZH2 gene amplification was significantly (P < 0.05) associated with increased EZH2 protein expression.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575874", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 993, 
            "offsetInEndSection": 1222, 
            "text": "The third tumor showed a t(6p;10q;10p) as the sole karyotypic abnormality, leading to the fusion of PHF1 with another partner, the enhancer of polycomb (EPC1) gene from 10p11; EPC1 has hitherto not been associated with neoplasia.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16397222", 
            "endSection": "sections.0"
        }
    ]
}